Trial · NCT02673333

Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma

NCT02673333, Phase 2, Active not recruiting, Memorial Sloan Kettering Cancer Center; results first posted 2020-01-06

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma. Trials, record NCT02673333. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02673333

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma
NCT number: NCT02673333
Status: Active not recruiting
Phases: Phase 2
Enrollment: 39 participants, actual
Lead sponsor: Memorial Sloan Kettering Cancer Center
Conditions: Adrenocortical Carcinoma
Interventions: Pembrolizumab
First posted: 2016-02-03
Last updated: 2026-04-06
Results first posted: 2020-01-06

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Objective Response Rate (ORR)	2 years	using RECIST v1.1 A Simon two stage minimax design will be employed to carry out this objective. In the first stage, 21 patients will be enrolled. If at least 3 out of 21 patients respond (partial response - PR or complete response - CR), we will enroll an additional 18 patients for a total of 39 patients. At the end of the study, 8 of 39 patients will need to respond to consider the therapy promising. The study will be complete when all subjects have either completed 24 months of drug therapy, progressed, or discontinued from the study for other reasons. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Objective Response Rate (ORR)	2 years		Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group5

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Units
Objective Response Rate (ORR)	Pembrolizumab	Complete Response	0	Participants
Objective Response Rate (ORR)	Pembrolizumab	Partial Response	9	Participants
Objective Response Rate (ORR)	Pembrolizumab	Stable Disease	7	Participants
Objective Response Rate (ORR)	Pembrolizumab	Progressive Disease	15	Participants
Objective Response Rate (ORR)	Pembrolizumab	Could Not Be Evaluated	8	Participants

Source ClinicalTrials.gov

Participant flow3

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Pembrolizumab	39
Overall Study	COMPLETED	Pembrolizumab	39
Overall Study	NOT COMPLETED	Pembrolizumab	0

Source ClinicalTrials.gov

Adverse events20

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Increased AST/ALT	Investigations	Pembrolizumab	9	39
other	Hypocalcemia	Metabolism and nutrition disorders	Pembrolizumab	4	39
other	Increased Alkaline Phosphatase	Investigations	Pembrolizumab	4	39
other	Lymphopenia	Investigations	Pembrolizumab	2	39
other	Hypoalbuminemia	Metabolism and nutrition disorders	Pembrolizumab	2	39
other	Increased Creatinine	Investigations	Pembrolizumab	2	39
other	Fatigue	General disorders	Pembrolizumab	8	39
other	Chills	General disorders	Pembrolizumab	2	39
other	Hypothyroidism	Endocrine disorders	Pembrolizumab	3	39
other	Nausea	Gastrointestinal disorders	Pembrolizumab	2	39

1 to 10 of 20Source ClinicalTrials.gov

See all 20 adverse events

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Pembrolizumab	20	39
Total, other adverse events	Pembrolizumab	23	39
Total, serious adverse events	Pembrolizumab	5	39

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
31644329	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02673333

GET https://conductscience.org/api/trials/v1/NCT02673333/registered

API reference For AI assistants